MedTrace Logo

Tumor Antigen-sensitized DC Vaccine As an Adjuvant Therapy for Esophagus Cancer

NCT05023928 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2025-03-12

No results posted yet for this study

Summary

The aim of this single center, single arm and prospective study is to explore the safety and efficacy of tumor antigen-sensitized DC vaccine in postoperative adjuvant treatment of esophageal cancer.

Conditions

  • Carcinoma
  • Esophagus Cancer

Interventions

BIOLOGICAL

Tumor antigen-sensitized DC vaccine

subcutaneous administration

Sponsors & Collaborators

  • Sichuan University

    lead OTHER

Principal Investigators

  • Zhen-Yu Ding, Prof · Sichuan University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-01
Primary Completion
2023-10-01
Completion
2024-10-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05023928 on ClinicalTrials.gov